Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,28747995,Ki,"Considering a typical dosing regimen and applying the obtained Ki values of 0.72 µM (darifenacin, 15 mg daily) and 7.2 µM [propiverine, 30 mg daily, immediate release (IR)] for the inhibition of CYP2D6 yielded a predicted 1.9-fold and 1.4-fold increase in the area under the curve (AUC) of debrisoquine (CYP2D6 substrate), respectively.",Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28747995/),μM,0.72,620,DB00209,Trospium
,28747995,Ki,"Considering a typical dosing regimen and applying the obtained Ki values of 0.72 µM (darifenacin, 15 mg daily) and 7.2 µM [propiverine, 30 mg daily, immediate release (IR)] for the inhibition of CYP2D6 yielded a predicted 1.9-fold and 1.4-fold increase in the area under the curve (AUC) of debrisoquine (CYP2D6 substrate), respectively.",Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28747995/),μM,7.2,621,DB00209,Trospium
,28747995,Ki,"Due to the inhibition of the particular intestinal CYP3A4, the obtained Ki values of 14 µM of propiverine (30 mg daily, IR) resulted in a predicted doubling of the AUC for midazolam (CYP3A4 substrate).",Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28747995/),μM,14,622,DB00209,Trospium
,15516023,C(max),C(max) (median: 6.42 ng/ml) and AUC(0.tlast) (42.28 ng/ml x h) were highest and t(max) (3.5 h) was shortest after administration of the reference tablet.,Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516023/),[ng] / [ml],6.42,789,DB00209,Trospium
,15516023,AUC(0.tlast),C(max) (median: 6.42 ng/ml) and AUC(0.tlast) (42.28 ng/ml x h) were highest and t(max) (3.5 h) was shortest after administration of the reference tablet.,Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516023/),[ng] / [h·ml],42.28,790,DB00209,Trospium
,15516023,t(max),C(max) (median: 6.42 ng/ml) and AUC(0.tlast) (42.28 ng/ml x h) were highest and t(max) (3.5 h) was shortest after administration of the reference tablet.,Absorption pattern of trospium chloride along the human gastrointestinal tract assessed using local enteral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15516023/),h,3.5,791,DB00209,Trospium
,25466967,Km,"TC was shown to be a substrate of OATP1A2 (Km = 6.9 ± 1.3 μmol/L; Vmax = 41.6 ± 1.8 pmol/mg·min), OCT1 (Km = 106 ± 16 μmol/L; Vmax = 269 ± 18 pmol/mg·min), and P-gp (Km = 34.9 ± 7.5 μmol/L; Vmax = 105 ± 9.1 pmol/mg·min, lipovesicle assay).",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[μM] / [l],6.9,18726,DB00209,Trospium
,25466967,Vmax,"TC was shown to be a substrate of OATP1A2 (Km = 6.9 ± 1.3 μmol/L; Vmax = 41.6 ± 1.8 pmol/mg·min), OCT1 (Km = 106 ± 16 μmol/L; Vmax = 269 ± 18 pmol/mg·min), and P-gp (Km = 34.9 ± 7.5 μmol/L; Vmax = 105 ± 9.1 pmol/mg·min, lipovesicle assay).",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[pM] / [mg·min],41.6,18727,DB00209,Trospium
,25466967,Km,"TC was shown to be a substrate of OATP1A2 (Km = 6.9 ± 1.3 μmol/L; Vmax = 41.6 ± 1.8 pmol/mg·min), OCT1 (Km = 106 ± 16 μmol/L; Vmax = 269 ± 18 pmol/mg·min), and P-gp (Km = 34.9 ± 7.5 μmol/L; Vmax = 105 ± 9.1 pmol/mg·min, lipovesicle assay).",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[μM] / [l],106,18728,DB00209,Trospium
,25466967,Vmax,"TC was shown to be a substrate of OATP1A2 (Km = 6.9 ± 1.3 μmol/L; Vmax = 41.6 ± 1.8 pmol/mg·min), OCT1 (Km = 106 ± 16 μmol/L; Vmax = 269 ± 18 pmol/mg·min), and P-gp (Km = 34.9 ± 7.5 μmol/L; Vmax = 105 ± 9.1 pmol/mg·min, lipovesicle assay).",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[pM] / [mg·min],269,18729,DB00209,Trospium
,25466967,Km,"TC was shown to be a substrate of OATP1A2 (Km = 6.9 ± 1.3 μmol/L; Vmax = 41.6 ± 1.8 pmol/mg·min), OCT1 (Km = 106 ± 16 μmol/L; Vmax = 269 ± 18 pmol/mg·min), and P-gp (Km = 34.9 ± 7.5 μmol/L; Vmax = 105 ± 9.1 pmol/mg·min, lipovesicle assay).",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[μM] / [l],34.9,18730,DB00209,Trospium
,25466967,Vmax,"TC was shown to be a substrate of OATP1A2 (Km = 6.9 ± 1.3 μmol/L; Vmax = 41.6 ± 1.8 pmol/mg·min), OCT1 (Km = 106 ± 16 μmol/L; Vmax = 269 ± 18 pmol/mg·min), and P-gp (Km = 34.9 ± 7.5 μmol/L; Vmax = 105 ± 9.1 pmol/mg·min, lipovesicle assay).",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[pM] / [mg·min],105,18731,DB00209,Trospium
,25466967,Km,"TC was taken up into HBU cells (Km = 18.5 ± 4.8 μmol/L; Vmax = 106 ± 11.3 pmol/mg·min) by mechanisms that could be synergistically inhibited by naringin (IC50 = 10.8 (8.4; 13.8) μmol/L) and verapamil (IC50 = 4.6 (2.8; 7.5) μmol/L), inhibitors of OATP1A2 and OCT1, respectively.",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[μM] / [l],18.5,18732,DB00209,Trospium
,25466967,Vmax,"TC was taken up into HBU cells (Km = 18.5 ± 4.8 μmol/L; Vmax = 106 ± 11.3 pmol/mg·min) by mechanisms that could be synergistically inhibited by naringin (IC50 = 10.8 (8.4; 13.8) μmol/L) and verapamil (IC50 = 4.6 (2.8; 7.5) μmol/L), inhibitors of OATP1A2 and OCT1, respectively.",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[pM] / [mg·min],106,18733,DB00209,Trospium
,25466967,IC50,"TC was taken up into HBU cells (Km = 18.5 ± 4.8 μmol/L; Vmax = 106 ± 11.3 pmol/mg·min) by mechanisms that could be synergistically inhibited by naringin (IC50 = 10.8 (8.4; 13.8) μmol/L) and verapamil (IC50 = 4.6 (2.8; 7.5) μmol/L), inhibitors of OATP1A2 and OCT1, respectively.",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[μM] / [l],10.8,18734,DB00209,Trospium
,25466967,IC50,"TC was taken up into HBU cells (Km = 18.5 ± 4.8 μmol/L; Vmax = 106 ± 11.3 pmol/mg·min) by mechanisms that could be synergistically inhibited by naringin (IC50 = 10.8 (8.4; 13.8) μmol/L) and verapamil (IC50 = 4.6 (2.8; 7.5) μmol/L), inhibitors of OATP1A2 and OCT1, respectively.",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[μM] / [l],4.6,18735,DB00209,Trospium
,19948948,area under the concentration-time curve from 0 to 24 hours,"With multiple dosing of trospium 60 mg extended-release once daily versus 20 mg twice daily, lower geometric least squares mean area under the concentration-time curve from 0 to 24 hours (17 360 vs 28 590 pg.h/mL; ratio 61%; 90% confidence interval, 51-72) and maximum plasma concentration (1517 vs 2502 pg/mL; 61%; 90% confidence interval, 49-75) are observed.",Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19948948/),[h·pg] / [ml],17 360,24492,DB00209,Trospium
,19948948,area under the concentration-time curve from 0 to 24 hours,"With multiple dosing of trospium 60 mg extended-release once daily versus 20 mg twice daily, lower geometric least squares mean area under the concentration-time curve from 0 to 24 hours (17 360 vs 28 590 pg.h/mL; ratio 61%; 90% confidence interval, 51-72) and maximum plasma concentration (1517 vs 2502 pg/mL; 61%; 90% confidence interval, 49-75) are observed.",Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19948948/),[h·pg] / [ml],28 590,24493,DB00209,Trospium
,19948948,maximum plasma concentration,"With multiple dosing of trospium 60 mg extended-release once daily versus 20 mg twice daily, lower geometric least squares mean area under the concentration-time curve from 0 to 24 hours (17 360 vs 28 590 pg.h/mL; ratio 61%; 90% confidence interval, 51-72) and maximum plasma concentration (1517 vs 2502 pg/mL; 61%; 90% confidence interval, 49-75) are observed.",Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19948948/),[pg] / [ml],1517,24494,DB00209,Trospium
,19948948,maximum plasma concentration,"With multiple dosing of trospium 60 mg extended-release once daily versus 20 mg twice daily, lower geometric least squares mean area under the concentration-time curve from 0 to 24 hours (17 360 vs 28 590 pg.h/mL; ratio 61%; 90% confidence interval, 51-72) and maximum plasma concentration (1517 vs 2502 pg/mL; 61%; 90% confidence interval, 49-75) are observed.",Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19948948/),[pg] / [ml],2502,24495,DB00209,Trospium
,19948948,time to maximum plasma concentration,"Furthermore, with trospium 60 mg extended-release versus 20 mg, median time to maximum plasma concentration is later (5.0 vs 4.5 hours) and half-life is longer (35.8 vs 27.2 hours).",Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19948948/),h,5.0,24496,DB00209,Trospium
,19948948,time to maximum plasma concentration,"Furthermore, with trospium 60 mg extended-release versus 20 mg, median time to maximum plasma concentration is later (5.0 vs 4.5 hours) and half-life is longer (35.8 vs 27.2 hours).",Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19948948/),h,4.5,24497,DB00209,Trospium
,19948948,half-life,"Furthermore, with trospium 60 mg extended-release versus 20 mg, median time to maximum plasma concentration is later (5.0 vs 4.5 hours) and half-life is longer (35.8 vs 27.2 hours).",Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19948948/),h,35.8,24498,DB00209,Trospium
,19948948,half-life,"Furthermore, with trospium 60 mg extended-release versus 20 mg, median time to maximum plasma concentration is later (5.0 vs 4.5 hours) and half-life is longer (35.8 vs 27.2 hours).",Pharmacokinetics of once-daily trospium chloride 60 mg extended release and twice-daily trospium chloride 20 mg in healthy adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19948948/),h,27.2,24499,DB00209,Trospium
,30973998,absolute bioavailability,"Trospium chloride was poorly absorbed after oral administration (absolute bioavailability, ∼8%-10%).",Effects of the P-Glycoprotein Inhibitor Clarithromycin on the Pharmacokinetics of Intravenous and Oral Trospium Chloride: A 4-Way Crossover Drug-Drug Interaction Study in Healthy Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30973998/),%,∼8,104777,DB00209,Trospium
,30973998,absolute bioavailability,"Trospium chloride was poorly absorbed after oral administration (absolute bioavailability, ∼8%-10%).",Effects of the P-Glycoprotein Inhibitor Clarithromycin on the Pharmacokinetics of Intravenous and Oral Trospium Chloride: A 4-Way Crossover Drug-Drug Interaction Study in Healthy Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30973998/),%,10,104778,DB00209,Trospium
,15966754,Peak plasma concentrations (Cmax),Peak plasma concentrations (Cmax) of approximately 4 ng/mL are reached 4-5 hours after administration of a 20 mg immediate-release preparation.,Clinical pharmacokinetics of trospium chloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966754/),[ng] / [ml],4,109102,DB00209,Trospium
,15966754,bioavailability,The mean bioavailability is approximately 10% and decreases by concomitant food intake (to a mean of 26% of the fasting area under the plasma concentration-time curve [AUC]).,Clinical pharmacokinetics of trospium chloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966754/),%,10,109103,DB00209,Trospium
,15966754,bioavailability,The mean bioavailability is approximately 10% and decreases by concomitant food intake (to a mean of 26% of the fasting area under the plasma concentration-time curve [AUC]).,Clinical pharmacokinetics of trospium chloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966754/),%,26,109104,DB00209,Trospium
,15966754,volume of distribution,The mean volume of distribution is approximately 350-800 L.,Clinical pharmacokinetics of trospium chloride. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966754/),l,350-800,109105,DB00209,Trospium
,15966754,renal clearance,"Urinary excretion of the parent compound plays a major role in the disposition of the drug, with a mean renal clearance of 29 L/h (accounting for approximately 70% of total clearance) and a mean elimination half-life ranging from 10 to 20 hours.",Clinical pharmacokinetics of trospium chloride. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966754/),[l] / [h],29,109106,DB00209,Trospium
,15966754,elimination half-life,"Urinary excretion of the parent compound plays a major role in the disposition of the drug, with a mean renal clearance of 29 L/h (accounting for approximately 70% of total clearance) and a mean elimination half-life ranging from 10 to 20 hours.",Clinical pharmacokinetics of trospium chloride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966754/),h,10 to 20,109107,DB00209,Trospium
,20303326,total run time,The total run time was 3.50 min and the elution of trospium and trospium-d8 (IS) occurred at 2.8 min.,Determination of the quaternary ammonium compound trospium in human plasma by LC-MS/MS: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20303326/),min,3.50,167703,DB00209,Trospium
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,10,171113,DB00209,Trospium
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,74,171114,DB00209,Trospium
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,33,171115,DB00209,Trospium
,14606931,bioavailabilities,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,26,171116,DB00209,Trospium
,14606931,bioavailabilities,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,91,171117,DB00209,Trospium
,14606931,Terminal disposition half-lives,"Terminal disposition half-lives of tolterodine and 5-hydroxymethyl-tolterodine (in CYP2D6 extensive metabolisers) are 2-3 and 3-4 hours, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),h,2-3,171118,DB00209,Trospium
,14606931,Terminal disposition half-lives,"Terminal disposition half-lives of tolterodine and 5-hydroxymethyl-tolterodine (in CYP2D6 extensive metabolisers) are 2-3 and 3-4 hours, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),h,3-4,171119,DB00209,Trospium
,31542894,half maximal inhibitory concentration,"Ranitidine inhibited OCT1, OCT2, MATE1, and MATE2-K with half maximal inhibitory concentration values of 186 ± 25 µM, 482 ± 105 µM, 134 ± 37 µM, and 35 ± 11 µM, respectively.",Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542894/),μM,186,196917,DB00209,Trospium
,31542894,half maximal inhibitory concentration,"Ranitidine inhibited OCT1, OCT2, MATE1, and MATE2-K with half maximal inhibitory concentration values of 186 ± 25 µM, 482 ± 105 µM, 134 ± 37 µM, and 35 ± 11 µM, respectively.",Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542894/),μM,482,196918,DB00209,Trospium
,31542894,half maximal inhibitory concentration,"Ranitidine inhibited OCT1, OCT2, MATE1, and MATE2-K with half maximal inhibitory concentration values of 186 ± 25 µM, 482 ± 105 µM, 134 ± 37 µM, and 35 ± 11 µM, respectively.",Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542894/),μM,134,196919,DB00209,Trospium
,31542894,half maximal inhibitory concentration,"Ranitidine inhibited OCT1, OCT2, MATE1, and MATE2-K with half maximal inhibitory concentration values of 186 ± 25 µM, 482 ± 105 µM, 134 ± 37 µM, and 35 ± 11 µM, respectively.",Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542894/),μM,35,196920,DB00209,Trospium
,31542894,renal clearance,"Instead, renal clearance was lowered by ∼15% (530 ± 99 vs 460 ± 120 mL/min; P < .05).",Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542894/),[ml] / [min],530,196921,DB00209,Trospium
,31542894,renal clearance,"Instead, renal clearance was lowered by ∼15% (530 ± 99 vs 460 ± 120 mL/min; P < .05).",Pharmacokinetic Drug-Drug Interactions Between Trospium Chloride and Ranitidine Substrates of Organic Cation Transporters in Healthy Human Subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31542894/),[ml] / [min],460,196922,DB00209,Trospium
,3741535,half-lives,"The mean half-lives were 2.7 and 97 min, respectively.",Determination of the bioavailability of the quaternary compound trospium chloride in man from urinary excretion data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741535/),min,2.7,218238,DB00209,Trospium
,3741535,half-lives,"The mean half-lives were 2.7 and 97 min, respectively.",Determination of the bioavailability of the quaternary compound trospium chloride in man from urinary excretion data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741535/),min,97,218239,DB00209,Trospium
,3741535,bioavailability,From the cumulative excretion of trospium into urine within 48 h a mean bioavailability of 2.9% was calculated.,Determination of the bioavailability of the quaternary compound trospium chloride in man from urinary excretion data. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741535/),%,2.9,218240,DB00209,Trospium
,22382787,t1/2,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (15.11 ± 3.24) h and (16.00 ± 3.96) h; Tmax was (4.0 ± 1.2) h and (4.1 ± 0.9) h; Cmax was (3.76 ± 1.87) ng·mL - 1 and (3.70 ± 1.89) ng·mL - 1; AUC0-t was (33.51 ± 14.39) ng·mL - 1·h and (33.33 ± 14.88) ng·mL - 1·h, and the AUC0-∞ was (35.20 ± 14.88) ng·mL - 1·h and (35.16±15.17) ng·mL - 1·h.",Pharmacokinetic and bioequivalence studies of trospium chloride after a single-dose administration in healthy Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382787/),h,15.11,252802,DB00209,Trospium
,22382787,t1/2,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (15.11 ± 3.24) h and (16.00 ± 3.96) h; Tmax was (4.0 ± 1.2) h and (4.1 ± 0.9) h; Cmax was (3.76 ± 1.87) ng·mL - 1 and (3.70 ± 1.89) ng·mL - 1; AUC0-t was (33.51 ± 14.39) ng·mL - 1·h and (33.33 ± 14.88) ng·mL - 1·h, and the AUC0-∞ was (35.20 ± 14.88) ng·mL - 1·h and (35.16±15.17) ng·mL - 1·h.",Pharmacokinetic and bioequivalence studies of trospium chloride after a single-dose administration in healthy Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382787/),h,16.00,252803,DB00209,Trospium
,22382787,Tmax,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (15.11 ± 3.24) h and (16.00 ± 3.96) h; Tmax was (4.0 ± 1.2) h and (4.1 ± 0.9) h; Cmax was (3.76 ± 1.87) ng·mL - 1 and (3.70 ± 1.89) ng·mL - 1; AUC0-t was (33.51 ± 14.39) ng·mL - 1·h and (33.33 ± 14.88) ng·mL - 1·h, and the AUC0-∞ was (35.20 ± 14.88) ng·mL - 1·h and (35.16±15.17) ng·mL - 1·h.",Pharmacokinetic and bioequivalence studies of trospium chloride after a single-dose administration in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382787/),h,4.0,252804,DB00209,Trospium
,22382787,Tmax,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (15.11 ± 3.24) h and (16.00 ± 3.96) h; Tmax was (4.0 ± 1.2) h and (4.1 ± 0.9) h; Cmax was (3.76 ± 1.87) ng·mL - 1 and (3.70 ± 1.89) ng·mL - 1; AUC0-t was (33.51 ± 14.39) ng·mL - 1·h and (33.33 ± 14.88) ng·mL - 1·h, and the AUC0-∞ was (35.20 ± 14.88) ng·mL - 1·h and (35.16±15.17) ng·mL - 1·h.",Pharmacokinetic and bioequivalence studies of trospium chloride after a single-dose administration in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382787/),h,4.1,252805,DB00209,Trospium
,22382787,Cmax,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (15.11 ± 3.24) h and (16.00 ± 3.96) h; Tmax was (4.0 ± 1.2) h and (4.1 ± 0.9) h; Cmax was (3.76 ± 1.87) ng·mL - 1 and (3.70 ± 1.89) ng·mL - 1; AUC0-t was (33.51 ± 14.39) ng·mL - 1·h and (33.33 ± 14.88) ng·mL - 1·h, and the AUC0-∞ was (35.20 ± 14.88) ng·mL - 1·h and (35.16±15.17) ng·mL - 1·h.",Pharmacokinetic and bioequivalence studies of trospium chloride after a single-dose administration in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382787/),-·1·ml·ng,3.76,252806,DB00209,Trospium
,22382787,Cmax,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (15.11 ± 3.24) h and (16.00 ± 3.96) h; Tmax was (4.0 ± 1.2) h and (4.1 ± 0.9) h; Cmax was (3.76 ± 1.87) ng·mL - 1 and (3.70 ± 1.89) ng·mL - 1; AUC0-t was (33.51 ± 14.39) ng·mL - 1·h and (33.33 ± 14.88) ng·mL - 1·h, and the AUC0-∞ was (35.20 ± 14.88) ng·mL - 1·h and (35.16±15.17) ng·mL - 1·h.",Pharmacokinetic and bioequivalence studies of trospium chloride after a single-dose administration in healthy Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382787/),-·1·ml·ng,3.70,252807,DB00209,Trospium
,22382787,AUC0-t,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (15.11 ± 3.24) h and (16.00 ± 3.96) h; Tmax was (4.0 ± 1.2) h and (4.1 ± 0.9) h; Cmax was (3.76 ± 1.87) ng·mL - 1 and (3.70 ± 1.89) ng·mL - 1; AUC0-t was (33.51 ± 14.39) ng·mL - 1·h and (33.33 ± 14.88) ng·mL - 1·h, and the AUC0-∞ was (35.20 ± 14.88) ng·mL - 1·h and (35.16±15.17) ng·mL - 1·h.",Pharmacokinetic and bioequivalence studies of trospium chloride after a single-dose administration in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382787/),-·1·h·ml·ng,33.51,252808,DB00209,Trospium
,22382787,AUC0-t,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (15.11 ± 3.24) h and (16.00 ± 3.96) h; Tmax was (4.0 ± 1.2) h and (4.1 ± 0.9) h; Cmax was (3.76 ± 1.87) ng·mL - 1 and (3.70 ± 1.89) ng·mL - 1; AUC0-t was (33.51 ± 14.39) ng·mL - 1·h and (33.33 ± 14.88) ng·mL - 1·h, and the AUC0-∞ was (35.20 ± 14.88) ng·mL - 1·h and (35.16±15.17) ng·mL - 1·h.",Pharmacokinetic and bioequivalence studies of trospium chloride after a single-dose administration in healthy Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382787/),-·1·h·ml·ng,33.33,252809,DB00209,Trospium
,22382787,AUC0-∞,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (15.11 ± 3.24) h and (16.00 ± 3.96) h; Tmax was (4.0 ± 1.2) h and (4.1 ± 0.9) h; Cmax was (3.76 ± 1.87) ng·mL - 1 and (3.70 ± 1.89) ng·mL - 1; AUC0-t was (33.51 ± 14.39) ng·mL - 1·h and (33.33 ± 14.88) ng·mL - 1·h, and the AUC0-∞ was (35.20 ± 14.88) ng·mL - 1·h and (35.16±15.17) ng·mL - 1·h.",Pharmacokinetic and bioequivalence studies of trospium chloride after a single-dose administration in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382787/),-·1·h·ml·ng,35.20,252810,DB00209,Trospium
,22382787,AUC0-∞,"The main pharmacokinetics parameters of test and reference were as follows: t1/2 was (15.11 ± 3.24) h and (16.00 ± 3.96) h; Tmax was (4.0 ± 1.2) h and (4.1 ± 0.9) h; Cmax was (3.76 ± 1.87) ng·mL - 1 and (3.70 ± 1.89) ng·mL - 1; AUC0-t was (33.51 ± 14.39) ng·mL - 1·h and (33.33 ± 14.88) ng·mL - 1·h, and the AUC0-∞ was (35.20 ± 14.88) ng·mL - 1·h and (35.16±15.17) ng·mL - 1·h.",Pharmacokinetic and bioequivalence studies of trospium chloride after a single-dose administration in healthy Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382787/),-·1·h·ml·ng,35.16,252811,DB00209,Trospium
